Ivy Brain Tumor Center to Present Multiple Abstracts and a Special Session on Innovative Clinical Trial Design at the 2024 European Association of Neuro-Oncology Annual Meeting
17. Oktober 2024 06:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute will present updated study results and a special session on clinical trial design at the...
Ivy Brain Tumor Center’s Dr. Nader Sanai Named Arizona Bioscience Researcher of the Year
17. September 2024 11:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, Chief of Neurosurgical Oncology at Barrow Neurological Institute, and the Francis &...
First patient dosed in Phase 3 Gliofocus Study for newly diagnosed glioblastoma patients at the Ivy Brain Tumor Center
17. Juli 2024 08:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, July 17, 2024 (GLOBE NEWSWIRE) -- Gliofocus is a global, registrational, randomized, controlled Phase 3 clinical trial comparing niraparib vs temozolomide in newly diagnosed...
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant improvement in overall survival of newly diagnosed glioblastoma patients
23. Mai 2024 17:09 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, May 23, 2024 (GLOBE NEWSWIRE) -- Results will be presented at American Society of Clinical Oncology (ASCO) Annual MeetingMedian overall survival was 20.3 months, nearly doubling the...
Ivy Brain Tumor Center Announces Promising Results of Phase 0/1 Glioblastoma Study at the American Association for Cancer Research Annual Meeting
05. April 2024 15:05 ET
|
Ivy Brain Tumor Center
Phoenix, Arizona, April 05, 2024 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced initial results from a Phase 0/1b clinical trial of AZD1390, in combination...
Ivy Brain Tumor Center Announces Promising Data for Niraparib in Phase 0/2 Glioblastoma Clinical Trial
17. November 2023 08:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a Phase 0/2 trial of niraparib in patients with newly...
Ivy Center Announces First Patient Treated in Targeted Phase 0/1 Clinical Trial for High-Grade Glioma
06. November 2023 10:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced the first patient has been treated in a novel Phase 0/1 clinical trial of...
Ivy Brain Tumor Center Announces Results of Phase 0/1 Study in Recurrent Glioblastoma Patients at the European Society for Medical Oncology (ESMO) 2023 Congress
18. Oktober 2023 02:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced initial results from a Phase 0/1 clinical trial of the Ataxia telangiectasia...
Ivy Brain Tumor Center Opens Novel Clinical Trial to Test Direct-to-Tumor Drug Delivery Method
18. Juli 2023 09:30 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, July 18, 2023 (GLOBE NEWSWIRE) -- In an effort to discover new treatments for brain tumors, such as glioblastoma, the Ivy Brain Tumor Center at Barrow Neurological Institute, announced...
Ivy Brain Tumor Center Announces Interim Results of Two Clinical Trials Targeting High-Grade Glioma
02. Juni 2023 15:50 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, June 02, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the nation’s largest early-phase drug development program dedicated to brain cancer, is...